TO/SB/08B (10-01)

Approved for use through 10/31/2002: OMB 0851-0031
U.S. Patent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE
To persons are required to respond to a collection of information unless it contains a valid OMB Under the Paperwork control number.

Substitute for form 1449B/POTRADEMAR INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Сол	nplete if Known
Application Number	10/785,106_
Filing Date	February 25, 2004
First Named Inventor	: Ming-Hui WEI, et al.
Group Art Unit	<del>-1645</del> - 1644
Examiner Name	TBA VanderVegt
Attorney Docket Number	CL001180DIV

(use as many sheets as necessary) of 1 Sheet 1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS: Include name of: the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite No. 1 T2 Examiner Item (book, magazine, journal, serial, symposium, catalog, etc.), date; page(s), volume-issue Initials number(s) nublisher city and/or country where oublished ABE IKURO, et al.; "Molecular cloning characterization, and functional expression of rat PV oxidosqualene cyclase cDNA"; Proceedings of the National Academy of Sciences of USA, National Academy of Science.; Washington, U.S., vol. 92, no. 2, 1995, pages 9274-9278, XP002162627; ISSN: 0027-8424 Copy of Supplementary Partial European Search Report dated February 15, 2005 PΙ BEST AVAILABLE COPY

-				25.6			_
ſ							•• •••
ı	Examiner	/F.	Pierre Vand	lerveat/	Date	06/26/2006	-
1	Signature	, - •		,	Considered	00/20/2000	,
L	Signature				i Consideredi	*,	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not clustion is in conformance with MPEP 609. Draw line through cristion if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optione). 2 Applicant is to place a check markthere if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete: Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231: DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231: